Secondary Malignancies in Patients with Meningioma: A Surveillance, Epidemiology, and End Results (Seer) Data Analysis

Background: Meningiomas are commonly encountered intracranial masses. There is limited knowledge regarding the risk of developing other malignancies, the so-called “secondary malignancies” (SM) in a patient with a meningioma. We evaluated the risk of developing a SM after a meningioma diagnosis.

Methods: The Surveillance, Epidemiology, and End Results (SEER-17) data registry, which consisted of 9,208,295 patients was utilized to generate a cohort of 124,769 patients diagnosed with meningioma to identify patients at risk for a SM. The SEER patient data were collected from the years 2000 to 2020. Statistical analysis was performed through SEER’s statistical analysis package and standardized incidence ratios (SIRs) for various malignancies after the diagnosis of primary meningioma was obtained. We also collected basic demographic, surgical, and postoperative data.

Results: Of the 124,769 patients, 11,411 (9.2%) received diagnoses of a SM, which correlates to a higher risk than the general population (SIR: 1.17; 99% CI: 1.15–1.19). Patients with meningiomas had an increased risk of the following cancers: cutaneous melanoma (SIR, 1.40; 99% CI, 1.26–1.56), kidney and renal pelvis (SIR, 1.66; 99% CI, 1.47–1.86), brain and other nervous system (SIR, 3.45; 99% CI, 2.99–3.97), thyroid (SIR, 2.48; 99% CI, 2.19–2.80), and non-Hodgkin’s lymphoma (SIR, 1.29; 99% CI, 1.15–1.44). Females were more predisposed to cancers of the lung (SIR, 1.19; 99% CI: 1.12–1.26), digestive system (SIR, 1.06; 99% CI, 1.01–1.12), and breast (SIR, 1.09; 99% CI 1.04–1.14).

Conclusion: Employing the SEER database, we demonstrated that there is an increased risk in developing certain SM after diagnosis of meningioma. Further research may illuminate possible shared genetic abnormalities between the development of meningioma and these SMs. The overall rate of SM in patients with meningioma, however, is not likely high enough to warrant additional screening recommendations ([Fig. 1]; [Tables 1] and [2]).

Fig. 1

Table 1

Table 2

Publikationsverlauf

Artikel online veröffentlicht:
05. Februar 2024